Altshuler LL, Abulseoud OA, Foland-Ross L, Bartzokis G, Chang S, Mintz J, Hellemann G, Vinters HV: Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. Bipolar Disord, 2010, 12, 541-549.
Araque A, Parpura V, Sanzgiri RP, Haydon PG: Tripartite synapses: Glia, the unacknowledged partner. Trends Neurosci, 1999, 22, 208-215.
Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G: Glial pathology in an animal model of depression: Reversal of stressinduced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry, 2010, 15, 501-511.
Banasr M, Duman RS: Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry, 2008, 64, 863-870.
Banasr M, Dwyer JM, Duman RS: Cell atrophy and loss in depression: Reversal by antidepressant treatment. Curr Opin Cell Biol, 2011, 23, 730-737.
Bechtholt-Gompf AJ, Walther HV, Adams MA, Carlezon WA Jr, Ongür D, Cohen BM: Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory. Neuropsychopharmacology, 2010, 35, 2049-2059.
Bowley MP, Drevets WC, Ongür D, Price JL: Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry, 2002, 52, 404-412.
Brown DR, Kretzschmar HA: The glio-toxic mechanism of a-aminoadipic acid on cultured astrocytes. J Neurocytol, 1998, 27, 109-118. Erratum in: J Neurocytol, 1998, 27, 281, 294.
Bunney BG, Bunney WE: Rapid-acting antidepressant strategies: Mechanisms of action. Int J Neuropsychopharmacol, 2012, 15, 695-713.
Catena-Dell'osso M, Fagiolini A, Rotella F, Baroni S, Marazziti D: Glutamate system as target for development of novel antidepressants. CNS Spectr, 2013, 18, 188-198.
Chang FW, Wang SD, Lu KT, Lee EH: Differential interactive effects of gliotoxin and MPTP in the substantia nigra and the locus coeruleus in BALB/c mice. Brain Res Bull, 1993, 31, 253-266.
Chaudhry FA, Lehre KP, van Lookeren Campagne M, Ottersen OP, Danbolt NC, Storm-Mathisen J: Glutamate transporters in glial plasma membranes: Highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry. Neuron, 1995, 15, 711-720.
Czéh B, Simon M, Schmelting B, Hiemke C, Fuchs E: Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology, 2006, 31, 1616-1626.
Damadzic R, Bigelow LB, Krimer LS, Goldenson DA, Saunders RC, Kleinman JE, Herman MM. A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: Absence of significant astrocytosis. Brain Res Bull, 2001, 55, 611-618.
Edgar N, Sibille E: A putative functional role for oligodendrocytes in mood regulation. Transl Psychiatry, 2012, 2, e109.
Fatemi SH, Laurence JA, Araghi-Niknam M, Stary JM, Schulz SC, Lee S, Gottesman II: Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr Res, 2004, 69, 317-323.
Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B: Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry, 2009, 33, 70-75.
Gosselin RD, Gibney S, O'Malley D, Dinan TG, Cryan JF: Region specific decrease in glial fibrillary acidic protein immunoreactivity in the brain of a rat model of depression. Neuroscience, 2009, 159, 915-925.
Hamidi M, Drevets WC, Price JL: Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry, 2004, 55, 563-569.
Hashimoto K, Sawa A, Iyo M: Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry, 2007, 62, 1310-1316.
Huck S, Grass F, Hatten ME: Gliotoxic effects of a-aminoadipic acid on monolayer cultures of dissociated postnatal mouse cerebellum. Neuroscience, 1984, 12, 783-791.
Huck S, Grass F, Hörtnagl H: The glutamate analogue a-aminoadipic acid is taken up by astrocytes before exerting its gliotoxic effect in vitro. J Neurosci, 1984, 4, 2650-2657.
John CS, Smith KL, Van't Veer A, Gompf HS, Carlezon WA Jr, Cohen BM, Öngür D, Bechtholt-Gompf AJ: Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. Neuropsychopharmacology, 2012, 37, 2467-2475.
Khurgel M, Koo AC, Ivy GO: Selective ablation of astrocytes by intracerebral injections of a-aminoadipate. Glia, 1996, 16, 351-358.
Largo C, Cuevas P, Somjen GG, Martín del Río R, Herreras O: The effect of depressing glial function in rat brain in situ on ion homeostasis, synaptic transmission, and neuron survival. J Neurosci, 1996, 16, 1219-1229.
Lee Y, Gaskins D, Anand A, Shekhar A: Glia mechanisms in mood regulation: A novel model of mood disorders. Psychopharmacology (Berl), 2007, 191, 55-65.
Leventopoulos M, Rüedi-Bettschen D, Knuesel I, Feldon J, Pryce CR, Opacka-Juffry J: Long-term effects of early life deprivation on brain glia in Fischer rats. Brain Res, 2007, 1142, 119-126.
Li LF, Yang J, Ma SP, Qu R: Magnolol treatment reversed the glial pathology in an unpredictable chronic mild stress-induced rat model of depression. Eur J Pharmacol, 2013, 711, 42-49.
Liu Q, Li B, Zhu HY,Wang YQ, Yu J,Wu GC. Clomipramine treatment reversed the glial pathology in a chronic unpredictable stress-induced rat model of depression. Eur Neuropsychopharmacol, 2009, 19, 796-805.
Maciag D, Hughes J, O'Dwyer G, Pride Y, Stockmeier CA, Sanacora G, Rajkowska G: Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: Relevance to neuroimaging studies. Biol Psychiatry, 2010, 67, 465-470.
Manji HK, Drevets WC, Charney DS: The cellular neurobiology of depression. Nat Med, 2001, 7, 541-547.
Massart R, Mongeau R, Lanfumey L: Beyond the monoaminergic hypothesis: Neuroplasticity and epigenetic changes in a transgenic mouse model of depression. Philos Trans R Soc Lond B Biol Sci, 2012, 367, 2485-2494.
Miguel-Hidalgo JJ, Baucom C, Dilley G, Overholser JC, Meltzer HY, Stockmeier CA, Rajkowska G: Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry, 2000, 48, 861-873.
Miguel-Hidalgo JJ, Rajkowska G: Comparison of prefrontal cell pathology between depression and alcohol dependence. J Psychiatr Res, 2003, 37, 411-420.
Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, Hen R et al.: Preclinical models: Status of basic research in depression. Biol Psychiatry, 2002, 52, 503-528.
Nichols NR, Osterburg HH, Masters JN, Millar SL, Finch CE: Messenger RNA for glial fibrillary acidic protein is decreased in rat brain following acute and chronic corticosterone treatment. Brain Res Mol Brain Res, 1990, 7, 1-7.
Nishimura RN, Santos D, Fu ST, Dwyer BE: Induction of cell death by L-alpha-aminoadipic acid exposure in cultured rat astrocytes: Relationship to protein synthesis. Neurotoxicology, 2000, 21, 313-320.
Olney JW, de Gubareff T, Collins JF: Stereospecificity of the gliotoxic and anti-neurotoxic actions of α-aminoadipate. Neurosci Lett, 1980, 19, 277-282.
Olney JW, Ho OL, Rhee V: Cytotoxic effects of acidic and sulphur containing amino acids on the infant mouse central nervous system. Exp Brain Res, 1971, 14, 61-76.
Pannicke T, Stabel J, Heinemann U, Reichelt W: A-Aminoadipic acid blocks the Na+-dependent glutamate transport into acutely isolated Müller glial cells from guinea pig retina. Pflugers Arch, 1994, 429, 140-142.
Paul IA, Skolnick P: Glutamate and depression: Clinical and preclinical studies. Ann NY Acad Sci, 2003, 1003, 250-272.
Rajkowska G, Miguel-Hidalgo JJ: Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets, 2007, 6, 219-233.
Rajkowska G,Miguel-Hidalgo JJ,Wei J, Dilley G, Pittman SD,Meltzer HY, Overholser JC et al.:Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry, 1999, 45, 1085-1098.
Rajkowska G, Stockmeier CA: Astrocyte pathology in major depressive disorder: Insights from human postmortem brain tissue. Curr Drug Targets, 2013, 14, 1225-1236.
Rodnight RB, Gottfried C: Morphological plasticity of rodent astroglia. J Neurochem, 2013, 124, 263-275.
Saffran BN, Crutcher KA: Putative gliotoxin, a-aminoadipic acid, fails to kill hippocampal astrocytes in vivo. Neurosci Lett, 1987, 81, 215-220.
Sanacora G, Banasr M: From pathophysiology to novel antidepressant drugs: Glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry, 2013, 73, 1172-1179.
Sanacora G, Saricicek A: GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets, 2007, 6, 127-140.
Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE: S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuroreport, 2002, 13, 1675-1678.
Si X, Miguel-Hidalgo JJ, O'Dwyer G, Stockmeier CA, Rajkowska G: Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology, 2004, 29, 2088-2096.
Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R: Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression. Pharmacopsychiatry, 1996, 29, 23-26.
Takada M, Hattori T: Fine structural changes in the rat brain after local injections of gliotoxin, a-aminoadipic acid. Histol Histopathol, 1986, 1, 271-275.
Trullas R, Skolnick P: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol, 1990, 185, 1-10.
Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI: Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: A study from the Stanley Neuropathology Consortium. Schizophr Res, 2004, 67, 269-275.
Vostrikov VM, Uranova NA, Orlovskaya DD: Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res, 2007, 94, 273-280.
Wieroñska JM, Pilc A: Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochem Int, 2009, 55, 85-97.
Yang J, Shen J: In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/ antipanic drug phenelzine. Neuroscience, 2005, 135, 927-937.
Zadrona M, Nowak B, Lasoñ-Tyburkiewicz M, Wolak M, Sowa-Kuæma M, Papp M, Ossowska G et al.: Different pattern of changes in calcium binding proteins immunoreactivity in the medial prefrontal cortex of rats exposed to stress models of depression. Pharmacol Rep, 2011, 63, 1539-1546.
Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 2006, 63, 856-864.
Zink M, Vollmayr B, Gebicke-Haerter PJ, Henn FA: Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology, 2010, 58, 465-473.
